

## **Elevated vitamin B12 levels and cancer risk in UK primary care:**

### **a THIN database cohort study**

Johan F. H. Arendt<sup>1,2,3</sup>, Henrik T. Sørensen<sup>1</sup>, Laura J. Horsfall<sup>3</sup>, Irene Petersen<sup>1,3</sup>.

<sup>1</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

<sup>2</sup>Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

<sup>3</sup>Department of Primary Care and Population Health, University College London, London, United Kingdom.

Corresponding author: Johan Frederik Håkonsen Arendt, Department of Clinical Epidemiology,

Aarhus University Hospital, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark. Email:

jfba@clin.au.dk. Phone: +45 87 15 58 72. Fax: + 45 87 16 72 15.

**Running title:** High plasma B12 levels and cancer risk in primary care

**Number of words in text:** 3,182

**Number of tables:** 4

**Number of figures:** 1

**Number of references:** 33

#### **Abbreviations:**

B12: vitamin B12, cobalamin

BMI: body mass index

CI: confidence interval

CIP: cumulative incidence proportion

GP: general practice

IR: incidence rate

IRR: incidence rate ratio

PPV: positive predictive value

THIN: The Health Improvement Network primary care database

UK: United Kingdom

**Keywords (MeSH):** Cohort studies; Neoplasms; Primary Health Care; Registries; Vitamin B12.

**Conflict of interest statement:** This work was supported from the “Frimodt-Heineke Fonden” and the ”Carl og Ellen Hertz’ legat til Dansk Læge- og Naturvidenskab” (J.F.H. Arendt), the Wellcome Trust [209207/Z/17/Z] (L. J. Horsfall) as well as The Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation (H.T. Sørensen). J.F.H. Arendt has received a lecture fee on one occasion from Siemens Healthineers, Siemens Healthcare A/S, Denmark.

The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study.

The sponsors of this study had no role in the initiation, planning, design, or conduct of the study, data acquisition, management and analyses, interpretation of results, writing and approval of the manuscript, or the decision to submit the manuscript for publication. The

researchers involved in this study declare their independence from the sponsors and have no conflicts of interests to report.

## Abstract

**Background:** Elevated vitamin B12 levels (B12) are associated with increased short-term cancer risk. However, the implications for early cancer detection in primary care have not been assessed.

**Methods:** Individuals with plasma B12 measurements were sampled from The Health Improvement Network primary care database, United Kingdom. Persons with low B12 levels were excluded together with persons with cancer or B12 treatment before date of B12 measurement. Incident cancer was the outcome of interest and was identified through Read codes. Individuals were disaggregated according to plasma B12 levels (unit: pmol/L): 150-600 (reference range values), 601-800, 801-1000, and >1000.

**Results:** Among the 757,185 persons who met the inclusion criteria, we identified 33,367 incident cancers during 2,874,059 years of follow-up. We found a higher one-year cancer risk among the 25,783 (3.4%) persons with elevated B12 levels compared to those with normal B12 levels. After multivariable adjustment for lifestyle factors and social deprivation, persons with B12 >1000 pmol/L had a one-year incidence rate ratio of 4.72 (95% confidence interval: 3.99-5.58). The association showed a non-linear dose-response pattern and it remained robust in stratified analyses, including when reducing the risk of confounding by indication in sub-analyses. The risks were particularly elevated for liver cancer, pancreas cancer and myeloid malignancies among persons with elevated B12 levels.

**Conclusions:** Elevated plasma B12 levels were associated with a higher one-year cancer risk than normal B12 levels among persons seen in UK primary care, suggesting that some cancers may affect B12 metabolism.

**Impact:** Elevated B12 may mark occult cancer.

## Introduction

It is common practice to measure plasma levels of vitamin B12 (B12, cobalamin) in persons suspected of B12 deficiency based on prevalent symptoms and/or risk factors for this condition (1). Cardinal symptoms of B12 deficiency are anaemia, neuropsychological complaints, such as fatigue, cognitive dysfunction and paraesthesia, and diarrhoea and glossitis. Persons at risk of developing B12 deficiency include vegetarians/vegans and those with malabsorption due to pernicious anaemia, inflammatory bowel disease, or atrophic gastritis (1).

Among persons with measured B12 levels, elevated levels above the upper reference limit are prevalent. The prevalence ranges from 1.2% to 18%, depending on study population and cut-off values for defining high B12 levels (2-7). These persons have gained attention in recent years, because an association between elevated B12 levels and cancer has been reported in several studies. Four cross-sectional studies reported a higher prevalence of cancer among hospital patients with high B12 levels compared to patients with normal B12 levels (2, 4-6). In addition, two cohort studies showed that patients with elevated plasma B12 levels had 6-15 times higher short-term risk of cancer compared to the general population in Denmark (3, 7). This association was found mainly for haematological cancers and smoking- and alcohol-related cancers (3). These findings indicate that elevated B12 levels may be a prodromal sign of undiagnosed cancer.

The cohort studies, conducted in Denmark, had several shortcomings (3, 7). They were unable to include data on whether patients were seen in hospital vs. primary care settings. Likewise, data on lifestyle factors were unavailable, such as smoking and alcohol use, which are strong risk factors for cancer. It is not clear whether smoking affects plasma B12 levels (8, 9), but high alcohol use is associated with high B12 levels (2, 10). It is thus unresolved whether

these factors influence the association between elevated B12 levels and cancer. In addition, the studies did not address whether risk estimates were confounded by the underlying indication for measuring plasma B12 levels.

In the current study, we assessed cancer risk among persons seen in the United Kingdom (UK) primary care system with elevated plasma B12 levels and included data on lifestyle factors. We also examined the potential confounding effect of the indication for requesting a plasma B12 measurement by examining a cohort of first-time statin users for whom the indication was unlikely related to any suspicion of cancer.

## **Materials and methods**

### **Data source**

The Health Improvement Network (THIN) primary care database contains pseudonymised data on more than 12 million persons from nearly 600 different practices in the UK (<http://csdmruk.cegedim.com>). Data collected from electronic GP records on symptoms, diagnoses, and referrals are coded using the hierarchical Read code system (11). Data on drug prescriptions, smoking and alcohol habits, measures of height and weight, and laboratory tests are also recorded. Information on social deprivation is recorded in quintiles of the Townsend score (12), which is based on owner-occupation, car ownership, overcrowding, and unemployment levels, as derived from UK census data and linked to the individual's postal code. More than 98% of members of the UK population are registered with a GP. THIN covers approximately 6% of these individuals and is considered representative of the UK population (13). We used THIN data from 2000 through 2015.

The study was approved by the IMS Health Scientific Review Committee (reference number: 16THIN096). The scheme of providing anonymised person data for research purposes, used by the THIN database administration, was approved by the National Health Service South-East Multi-Centre Research Ethics Committee.

### **Study population**

Our study population included all individuals between 18-99 years of age with a first-time plasma B12 measurement performed between 1 January 2000 and 30 June 2015. Data were included only if the period for data collection in the individual practice met the criteria of acceptable computer usage and mortality reporting, as previously described (14, 15). We

excluded individuals with any of the following conditions recorded before the date of plasma B12 measurement: 1. diagnosis, treatment, care for, or history of cancer; 2. cancer diagnosis recorded within six months of the person's registration at the GP, which may reflect prevalent cancer (16); 3. B12 measurement within six months of the person's registration at the GP to avoid immortal time; 4. diagnosis and/or treatment for B12 deficiency, the single most common cause of high B12 measurements (2); or 5. plasma B12 levels below 150 pmol/L and/or below the lower reference limit. Individuals were followed from the date of first plasma B12 measurement until the date of cancer diagnosis, death, transfer to a different GP, end of data contribution by the GP, or 31 December 2015, whichever came first.

### **Plasma vitamin B12 levels**

We defined the following groups based on plasma B12 levels: reference range values of 150-600 pmol/L and three groups with high plasma B12 levels: 601-800 pmol/L, 801-1000 pmol/L, and >1000 pmol/L (in pg/ml: 203-813, 814-1084, 1085-1355, and >1355). We chose the cut-off for reference range values based on the distribution of reference range cut-offs in the study population.

### **Cancer**

We developed lists of Read codes for cancer diagnoses using the method described by Dave and Petersen (17). Cancer events were identified as a first-time cancer diagnosis in the persons' records or a record of death due to cancer. The cancer incidence in THIN is similar to the incidence in the UK Quality Outcomes Framework data (13), and to the UK Office for National Statistics' Cancer Registration Statistics (18, 19). Previous studies have assessed the positive

predictive values (PPVs) of specific cancer diagnosis codes in THIN, and found a PPV of 94% for bladder cancer (20) and a PPV of 89% for colorectal cancer (21).

### **Covariates**

Covariates included sex, age, Townsend quintile score, body mass index (WHO definition: BMI: <18.5, 18.5-24.9, 25-29.9, and  $\geq 30$  kg/m<sup>2</sup>), smoking status (never, former, and current), and alcohol use (non-drinker, former drinker, moderate drinker [within UK guidelines, alcohol units per week: male:  $\leq 21$ /female:  $\leq 14$ ], and heavy drinker [consuming more than UK guidelines; alcohol units per week: male: 22-49/female: 15-35], and very heavy drinker [alcohol units per week: male:  $\geq 50$ /female:  $> 35$ ]). The value of each covariate recorded closest to the date of plasma B12 measurement was used. Records of smoking and alcohol habits in THIN are considered valid (22, 23).

### **First-time statin users**

Previous cohort studies on the association between high plasma B12 levels and cancer risk did not assess the confounding effect of the indication for measuring plasma B12 (3, 7), and the indication may be related to a clinical suspicion of cancer. To overcome this limitation, we identified a cohort of first-time statin users in the main study population, assuming that these individuals: 1. are unlikely to be suspected of cancer; 2. have blood samples taken regularly as a part of the routine statin check-up recommended for new statin users by the National Institute for Health and Care Excellence (<https://www.nice.org.uk/guidance/cg181/>. Accessed December 7 2018); and 3. are likely to have their plasma B12 levels measured without an indication of any suspected severe disease. Previous reports indeed indicate that B12 is often measured without

any indications related to symptoms and/or risk factors for B12 deficiency (24, 25). The inclusion criteria for this cohort were a first-time statin prescription; and a plasma B12 measurement within six months after the date of the first statin prescription. Exclusion criteria were the same as for the main study population, as described above.

### **Statistical analysis**

We computed incidence ratios (IRs) and cumulative incidence proportions (CIPs) as measures of the absolute risk of cancer, treating death due to other causes than cancer as a competing risk for computing CIPs (26). We stratified according to the four groups of B12 levels with corresponding 95% confidence intervals (CIs).

In addition, we used multivariable Poisson regression analysis to compute adjusted incidence rate ratios (IRRs) with corresponding 95% CIs to assess relative cancer risk with higher plasma B12 levels, using persons with plasma B12 levels of 150-600 pmol/L as reference. We adjusted for sex, age, Townsend quintile score, BMI, smoking status, and alcohol use. We used stratified analyses to assess if any of the co-variates modified the association between B12 and cancer incidence. All risk estimates were stratified according to the following covariates: years of follow-up (<1,  $\geq 1$ - $\leq 2$ ,  $> 2$ - $\leq 4$ , and  $\geq 5$ ), sex, age (18-39, 40-59, 60-79, and 80-99), Townsend quintile score (1 as the least deprived and 5 as the most deprived), BMI (<18.5, 18.5-24.9, 25-29.9, and  $\geq 30$  kg/m<sup>2</sup>), smoking status (never, former, and current), alcohol use (non-drinker, former drinker, moderate drinker, heavy drinker, and very heavy drinker). We included person-time for all participants in the relevant follow-up time periods. We also stratified risk estimates according to specific cancer types, taking into account the sex-specific types (e.g. excluding females from analyses of prostate cancer). For the regression analyses, we excluded

219,249 people with missing values, including people with no records of Townsend quintile (n= 30,590), BMI (n= 59,426), smoking (n= 26,399), and alcohol use (n=170,810). Their characteristics are shown in Supplementary Table S1. We evaluated whether data were clustered by practice using a random effect model, but did not observe any clustering. We conducted restricted cubic spline regression to assess any non-linear associations between plasma B12 as a continuous variable and risk of cancer (27). We used five knots at 150, 400, 600, 800, and 1000 pmol/L, with plasma B12 of 400 pmol/L (542 pg/mL) as reference, and chose a graphical presentation of the smoothed IRRs (overall and after one year of follow-up) as a function of a 1 pmol/L (1.36 pg/mL) increase in plasma B12 levels.

We computed CIPs, IRs, and IRRs for the cohort of first-time statin users using the same approach as for the main study population, with follow-up starting at the date of plasma B12 measurement.

All analyses were performed with Stata IC Version 14.2.

## Results

The study included 757,185 (64% female) with a first-time plasma B12 measurement (median age = 55.8 years; median follow-up time = 2.8 years [interquartile range: 1.3-5.3 years]). A total of 28,897 (3.5%) had elevated plasma B12 levels (>600 pmol/L). The proportions of heavy drinkers and people from the most deprived areas were higher among people with high plasma B12 levels, whereas the proportions of current smokers and overweight/obese individuals were lower among people with high plasma B12 levels (Table 1).

During 2,874,059 years of follow-up, 33,367 people (4.4 %) were diagnosed with cancer. The risk of cancer was higher in people with elevated plasma B12 levels, most pronounced within the first year of follow-up (Table 2). Incidence rates and CIPs in the part of the population with complete data on covariates were very similar to estimates based on the entire population (Supplementary Table S2). Comparing persons with a normal plasma B12 level to those with B12 >1000 pmol/L and adjusting for covariates, this corresponded to an overall IRR of 2.42 (95% CI: 2.11-2.77) and an IRR within the first year of follow-up of 4.72 (95% CI: 3.99-5.58). The association showed a non-linear dose-response pattern, as depicted in Figure 1.

Absolute cancer risk was higher for males than for females and increased with increasing age, but IRRs were almost similar, both overall and within the first year of follow-up. Smokers had higher one-year CIPs risk than non-smokers (CIP for persons with plasma B12 >1000 pmol/L, smoker vs. non-smoker: 6.79 (4.90-9.08) vs. 5.54 (4.55-6.67)). For individuals with normal alcohol use compared with very heavy drinkers, we found paradoxically higher one-year CIPs with increasing B12 levels (CIP for persons with plasma B12 >1000 pmol/L, moderate vs. very heavy drinkers: 7.48 (6.07-9.07) vs. 4.05 (2.15-6.89)). Likewise, we found higher one-year CIPs in those who were from the least deprived areas (Townsend quintile 1) compared to persons

who were from the most deprived areas (Townsend quintile 5). However, the IRRs were very comparable in the stratified analyses and provided no evidence of an effect modification of the associations between B12 and cancer by alcohol consumption or social deprivation (see Supplementary Table S3 for results from stratified analyses). In both the overall analysis and the analysis stratified according to levels of covariates, the association between elevated B12 levels and cancer attenuated after the first year of follow-up. No overall association was found after two years of follow-up (Table 2).

The IRRs for specific cancers are shown in Table 3. We found the strongest association between high plasma B12 and risk of cancers of the upper gastrointestinal tract, the liver, the pancreas, the lung, and myeloid malignancies. The association remained robust, as it was strongest within the first year of follow-up, but the association persisted through more than five years of follow-up for liver cancer and myeloid malignancies. In contrast, colorectal, prostate and kidney cancer, as well as lymphatic leukaemia and multiple myeloma were not associated with high plasma B12. However, for some cancers there were very few events. No or only weak associations were found between high B12 levels and several other common cancers, including breast cancer and malignant melanoma (Supplementary Table S4).

There were 10,775 first-time statin users with a plasma B12 measurement. Their characteristics are shown in Supplementary Table S5. Compared to the main study population, first-time statin users were older, more often male and ex-smokers, had higher BMI, but with similar alcohol habits and Townsend quintile distributions. The association between elevated plasma B12 and cancer was robust in the statin-using cohort, with the highest risk of cancer within one year of follow-up, both for CIPs, IRs, and IRRs (Table 4). Due to a small sample size with few events, the estimates had wide 95% CIs.

## Discussion

In this large cohort study using UK primary care data, we found that having elevated plasma B12 levels was associated with a higher short-term cancer risk compared to having normal B12 levels and the association showed a non-linear dose-response pattern. The association persisted when we controlled for several covariates, such as sex, age, smoking, and alcohol use. We also found the association in a cohort of first-time statin users, for whom cancer suspicion is unlikely to be related to the indication for measuring plasma B12 levels.

In the current study, we were able to confirm and elaborate on what we (3) and others (7) have found in the Danish patient population. Our results showed that high B12 levels are a marker of occult, not yet diagnosed cancer, also in the UK population and in the primary care setting. Unlike previous studies on high B12 levels and cancer risk, we were able to include information on smoking and alcohol habits (3, 7). It is interesting that several of the cancer types associated with high plasma B12 are also associated with these two lifestyle factors, but our results remained robust, both when adjusting and stratifying according to smoking status and alcohol intake. However, it is important to note that only a minority of persons with plasma B12 >1000 pmol/L were diagnosed with cancer within the first year following plasma B12 measurement. This potentially makes high B12 levels a marker of occult cancer, and further study will have to address the implications of including high B12 in clinical guidelines for early cancer detection in general practice.

Previous studies suggest that in up to two-thirds of individuals with a plasma B12 measurement, there was no specific indication for requesting the measurement, such as symptoms and/or risk factors for B12 deficiency (24, 25). The higher IR within the first year of follow-up even for patients with B12 within the reference range may be due to the effect being in

diagnostic process, i.e. the reason plasma B12 was measured. Further, the drop in IRs after the first year of follow-up is likely a compensatory deficit – that many cancers are diagnosed shortly after B12 measurement so the incidence drops thereafter. Ultimately, we cannot assess the indication for measuring plasma B12 for the individual person, but our results in the cohort of first-time statin users were robust. These results together with the robustness of the stratified analyses suggest that a potential confounding effect of the indication for measuring plasma B12 cannot fully explain the association between cancer and elevated plasma B12.

Some potential study limitations warrant attention. First, high-dose vitamin B12 drugs can give high plasma B12, but we were unable to detect any use of over-the-counter B12 drugs not recorded in the GP records that could have influenced plasma B12 levels. Hence, we might have included persons with high plasma B12 levels due to use of over-the-counter high-dose B12 drugs in the high B12 groups. Since these drugs do not increase cancer risk (28), we might have included some individuals at low risk of cancer in the high B12 groups, resulting in a potential underestimation of the association between high plasma B12 and cancer. Moreover, we can't preclude that some individuals might have bought high dose B12 vitamins to self-treat symptoms such as fatigue - a symptom also related to occult cancer. However, it is more likely that such drugs were prescribed by a GP to treat fatigue, and if so, these individuals would have been excluded. In addition, we may have underestimated the association due to random measurement error, leading to misclassification of B12 levels and potential regression dilution bias (29). There is also a risk that high plasma B12 or other concurrent abnormal lab tests could have increased the general practitioner's awareness of cancer, leading to more intense diagnostic efforts in these people. However, high plasma B12 is not currently included in the clinical guideline for early cancer detection (<https://www.nice.org.uk/guidance/ng12/>. Accessed December 7 2018), so we

consider the risk of diagnostic bias to be minimal in our study. Last, we were not able to assess whether first-time statin users were indeed first-time users or prevalent users who newly registered with a GP practice providing data for the THIN database.

It is not entirely understood how the underlying cancer can cause high plasma B12 levels. Circulating B12 is exclusively bound to either haptocorrin or transcobalamin. The cancer may affect B12 metabolism by affecting the levels of these B12-binding proteins that in turn give rise to elevated plasma B12 levels (1). These protein alterations may involve inflammation cells that can produce either haptocorrin (30) or transcobalamin (31), and the potential underlying inflammation may also explain why high plasma B12 is associated with higher mortality risk and risk of venous thromboembolism among cancer patients (32, 33). These results are in concurrence with our previous finding that haptocorrin is elevated in cancer patients with high plasma B12 (2), and earlier reports showing that malignant proliferating leukocytes in patients with chronic myeloid leukaemia (10). We were unable to include data on tumour size, lymph node involvement or distant metastasis. These factors may also be important in the assessment of why and how elevated B12 is associated with cancer. Ultimately, it remains unresolved why high plasma B12 is associated with only some types of cancer and whether different protein alterations can be found in specific cancer types or stages of cancer.

In summary, in this study based on UK primary care data we found a non-linear dose-response association between elevated plasma B12 and one-year cancer risk, suggesting that high B12 levels can mark occult cancer.

## Acknowledgements

This work was supported from the “Frimodt-Heineke Fonden” and the ”Carl og Ellen Hertz’ legat til Dansk Læge- og Naturvidenskab” (J.F.H. Arendt), the Wellcome Trust [209207/Z/17/Z] (L. J. Horsfall) as well as The Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation (H.T. Sørensen). J.F.H. Arendt has received a lecture fee on one occasion from Siemens Healthineers, Siemens Healthcare A/S, Denmark.

The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study.

The sponsors of this study had no role in the initiation, planning, design, or conduct of the study, data acquisition, management and analyses, interpretation of results, writing and approval of the manuscript, or the decision to submit the manuscript for publication. The researchers involved in this study declare their independence from the sponsors and have no conflicts of interests to report.

## References

1. Green R, Allen LH, Bjorke-Monsen AL, Brito A, Gueánt JL, Miller JW *et al.* Vitamin B12 deficiency. *Nat Rev Dis Primers* **2017**;3:17040.
2. Arendt JF, Nexo E. Cobalamin Related Parameters and Disease Patterns in Patients with Increased Serum Cobalamin Levels. *PLoS One* **2012**;7(9):e45979.
3. Arendt JF, Pedersen L, Nexo E, Sorensen HT. Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study. *J Natl Cancer Inst* **2013**;105:(23):1799-1805.
4. Brah S, Chiche L, Mancini J, Meunier B, Arlet JB. Characteristics of patients admitted to internal medicine departments with high serum cobalamin levels: Results from a prospective cohort study. *Eur J Intern Med* **2014**;25(5):e57-e58.
5. Chiche L, Jean R, Romain F, Roux F, Thomas G, Canavese S *et al.* Clinical implications of high cobalamin blood levels for internal medicine. *Rev Med Interne* **2008**;29(3):187-194.
6. Jammal M, Deneuille T, Mario N, Tiev K, Tolédano C, Josselin-Mahr L *et al.* High plasmatic concentration of vitamin B12: An indicator of hepatic diseases or tumors. *Rev Med Interne* **2013**;34(6):337-341.
7. Ryg J, Nybo M, Hallas J. Cancer incidence in persons with elevated cobalamin levels. *Eur J Clin Invest* **2013**;43(6):557-561.
8. Eussen SJ, Nilsen RM, Midttun O, Hustad S, IJssennagger N, Meyer K *et al.* North-south gradients in plasma concentrations of B-vitamins and other components of one-carbon metabolism in Western Europe: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. *Br J Nutr* **2013**;110(2):363-374.

9. Ulvik A, Ebbing M, Hustad S, Midttun Ø, Nygård O, Vollset SE *et al.* Long- and short-term effects of tobacco smoking on circulating concentrations of B vitamins. *Clin Chem* **2010**;56(5):755-763.
10. Arendt JF, Nexø E. Unexpected high plasma cobalamin: Proposal for a diagnostic strategy. *Clin Chem Lab Med* **2013**;51(3):489-496.
11. Booth N. What are the read codes? *Health Libr Rev* 1994;11(3):177–182.
12. Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequalities and the North. Croom Helm: PN London, 1988.
13. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. *Inform Prim Care* **2011**;19(4):251-255.
14. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. *Pharmacoepidemiol Drug Saf* **2013**;22(1):64-69.
15. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. *Pharmacoepidemiol Drug Saf* **2009**;18(1):76-83.
16. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. *Pharmacoepidemiol Drug Saf* **2005**;14(7):443-451.
17. Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. *Pharmacoepidemiol Drug Saf* **2009**;18(8):704-707.
18. Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. *Pharmacoepidemiol Drug Saf* **2009**;18(8):730-736.

19. Iyen-Omofoman B, Hubbard RB, Smith CJ, Sparks E, Bradley E, Bourke A *et al.* The distribution of lung cancer across sectors of society in the United Kingdom: a study using national primary care data. *BMC Public Health* **2011**;11:857.
20. Mamtani R, Haynes K, Boursi B, Scott FI, Goldberg DS, Keefe SM *et al.* Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database. *Cancer Epidemiol Biomarkers Prev* **2015**;24(1):303-307.
21. Cea Soriano L, Soriano-Gabarro M, Garcia Rodriguez LA. Validity and completeness of colorectal cancer diagnoses in a primary care database in the United Kingdom. *Pharmacoepidemiol Drug Saf* **2016**;25(4):385-391.
22. Khadjesari Z, Marston L, Petersen I, Nazareth I, Walters K. Alcohol consumption screening of newly-registered patients in primary care: a cross-sectional analysis. *Br J Gen Pract* **2013**;63(615):e706-e712.
23. Marston L, Carpenter JR, Walters KR, Morris RW, Nazareth I, White IR, *et al.* Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study. *BMJ Open* **2014**;4(4):e004958.
24. Chiche L, Mancini J, Arlet JB. Indications for cobalamin level assessment in departments of internal medicine: a prospective practice survey. *Postgrad Med J.* **2013**; 89(1056): 560-565.
25. McHugh J, Afghan R, O'Brien E, Kennedy P, Leahy M, O'Keefe D. Impact of the introduction of guidelines on vitamin B12 testing. *Clin Chem.* **2012**; 58(2):471-472
26. Marubini E., Valsecchi M.G. *Analysing Survival Data from Clinical Trials and Observational Studies.* John Wiley & Sons Ltd; 2004.

27. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2nd edition: Springer International Publishing; 2015.
28. Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. *Lancet* **2013**;381(9871):1029-1036.
29. Hutcheon JA, Chioloro A, Hanley JA. Random measurement error and regression dilution bias. *BMJ* **2010**;340:c2289.
30. Morkbak AL, Poulsen SS, Nexø E. Haptocorrin in humans. *Clin Chem Lab Med* **2007**;45(12):1751-1759.
31. Møller HJ, Møestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS *et al.* Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. *Crit Care Med* **2006**;34(10):2561-2566.
32. Arendt JF, Farkas DK, Pedersen L, Nexø E, Sørensen HT. Elevated plasma vitamin B12 levels and cancer prognosis: A population-based cohort study. *Cancer Epidemiol* **2016**;40:158-165.
33. Arendt JF, Farkas DK, Pedersen L, Sørensen HT. Elevated plasma vitamin B12 levels and risk of venous thromboembolism among cancer patients: A population-based cohort study. *Thromb Res* **2017**;156:177-183.

**Table 1.** Characteristics of 757,185 individuals in the United Kingdom with a first-time plasma B12 measurement, 1 January 2000 to 30 June 2015.

	Plasma B12 level groups (pmol/L)			
	150-600	601-800	801-1000	>1000
<b>No.</b>	731,402	17,963	4,410	3,410
<b>Sex (female), %</b>	466,980 (64)	12,265 (68)	3,023 (69)	2,302 (68)
<b>Age in years, median (range)</b>	56.3 (18-99)	56.5 (18-99)	58.0 (18-99)	61.5 (18-99)
<b>Year of B12 measurement, n (%)<sup>a</sup></b>				
2000-2004	53,940 (7)	1,581 (9)	495 (11)	376 (11)
2005-2008	137,502 (19)	3,478 (19)	891 (20)	706 (21)
2009-2011	236,058 (32)	5,557 (31)	1,241 (28)	950 (28)
2012-mid2015	303,902 (42)	7,347 (41)	1,783 (40)	1,378 (40)
<b>Smoking, n (%)<sup>a</sup></b>				
Never smoker	381,992 (52)	10,272 (57)	2,540 (58)	1,866 (55)
Former smoker	185,187 (25)	3,918 (22)	868 (20)	759 (22)
Smoker	139,110 (19)	2,959 (16)	732 (17)	583 (17)
Missing	25,113 (3)	814 (5)	270 (6)	202 (6)
<b>Alcohol use, n (%)<sup>a</sup></b>				
Non-drinker	136,753 (19)	4,359 (24)	1,095 (25)	777 (23)
Former drinker	24,478 (3)	690 (4)	163 (4)	140 (4)
Moderate drinker (within guidelines)	343,248 (47)	7,233 (40)	1,634 (37)	1,229 (36)
Heavy drinker	38,868 (5)	674 (4)	148 (3)	147 (4)
Very heavy drinker	23,283 (3)	873 (5)	299 (7)	284 (8)
Missing	164,772 (23)	4,134 (23)	1,071 (24)	833 (24)
<b>BMI in categories, n (%)<sup>a</sup></b>				
<18.5 kg/m <sup>2</sup>	22,984 (3)	1,014 (6)	218 (6)	207 (6)
18.5-24.9 kg/m <sup>2</sup>	258,348 (35)	7,411 (41)	1,765 (40)	1,318 (39)
25-29.9 kg/m <sup>2</sup>	222,338 (30)	4,884 (27)	1,199 (27)	930 (27)
≥30 kg/m <sup>2</sup>	170,635 (23)	3,121 (17)	740 (17)	584 (17)
Missing	57,097 (8)	1,533 (9)	425 (10)	317 (11)
<b>Townsend quintile, n (%)<sup>a</sup></b>				
1	170,732 (23)	3,753 (21)	906 (21)	693 (20)
2	153,188 (21)	3,564 (20)	802 (18)	658 (19)
3	151,111 (21)	3,615 (20)	911 (21)	722 (21)
4	134,076 (18)	3,385 (19)	845 (19)	672 (20)
5	93,080 (13)	2,655 (15)	710 (16)	517 (15)
Missing	29,215 (4)	991 (6)	236 (5)	148 (4)

**Table 1.** <sup>a</sup>Numbers do not add up to 100 due to rounding. Abbreviations: BMI: body mass index.

**Table 2.** Cumulative incidence proportions, person-years, number of cancer events, incidence rates, and adjusted incidence rate ratios (all with corresponding 95% confidence intervals) for the risk of cancer in the main study population.

Main study population	Plasma B12 level groups (pmol/L)			
	150-600	601-800	801-1000	>1000
<b>CIP in % (95% CI)</b>				
End of follow-up	13.09 (12.70-13.49)	13.96 (11.82-16.28)	17.71 (11.47-25.05)	17.75 (14.14-21.70)
1 year of follow-up	1.61 (1.58-1.64)	2.30 (2.08-2.53)	3.45 (2.93-4.03)	6.62 (5.80-7.50)
2 years of follow-up	2.49 (2.46-2.53)	3.24 (2.97-3.52)	4.32 (3.72-4.98)	7.95 (7.03-8.93)
5 years of follow-up	5.08 (5.01-5.14)	5.58 (5.17-6.02)	6.91 (6.02-7.88)	10.24 (9.10-11.47)
<b>Person-years</b>				
Overall	2,783,636	64,749	15,148	10,527
<1 year	673,276	15964	3,763	2,714
≥1-≤2 years	533,060	12,424	2,871	1,989
>2-≤4 years	965,797	22,114	5,041	3,447
≥5 years	611,503	14,247	3,473	2,377
<b>Cancer events</b>				
Overall	31,894	877	275	321
<1 year	11,257	397	146	217
≥1-≤2 years	4,982	129	29	34
>2-≤4 years	9,248	204	55	38
≥5 years	6,407	147	45	32
<b>IR/1,000 PYs (95% CI)</b>				
Overall	11.46 (11.33-11.58)	13.55 (12.68-14.47)	18.16 (16.13-20.43)	30.49 (27.33-34.02)
<1 year	16.72 (16.41-17.03)	24.87 (22.54-27.44)	38.79 (32.99-45.63)	79.95 (69.99-91.33)
≥1-≤2 years	9.35 (9.09-9.61)	10.38 (8.74-12.34)	10.10 (7.02-14.54)	17.09 (12.21-23.92)
>2-≤4 years	9.58 (9.38-9.77)	9.23 (8.04-10.58)	10.91 (8.38-14.21)	11.02 (8.02-15.15)
≥5 years	10.48 (10.22-10.74)	10.32 (8.78-12.13)	12.96 (9.68-17.36)	13.46 (9.52-19.04)
<b>Adj. IRR<sup>a</sup> (95%CI)</b>				
Overall	Ref.	1.31 (1.21-1.41)	1.88 (1.64-2.15)	2.42 (2.11-2.77)
<1 year	Ref.	1.74 (1.54-1.96)	2.90 (2.39-3.51)	4.72 (3.99-5.58)
≥1-≤2 years	Ref.	1.39 (1.15-1.69)	1.39 (0.93-2.07)	1.58 (1.04-2.41)
>2-≤4 years	Ref.	0.99 (0.84-1.17)	1.37 (1.03-1.83)	1.23 (0.87-1.75)
≥5 years	Ref.	1.10 (0.91-1.32)	1.54 (1.11-2.12)	1.19 (0.79-1.82)

**Table 2.** <sup>a</sup>Incidence rate ratios were based on the 537,936 persons with complete data on all covariates. Estimates were computed

using persons with a plasma B12 level of 150-600 pmol/L as reference and adjusted for sex, age, Townsend quintile, smoking, alcohol use, and BMI. The analyses were stratified according to plasma B12 levels and length of follow-up. Abbreviations: BMI: body mass index; CI: confidence interval; CIP: cumulative incidence proportion; IR: incidence rate; IRR: incidence rate ratio; PYs: person-years.

**Table 3.** Adjusted incidence rate ratios (all with corresponding 95% confidence intervals) for the risk of specific cancer types in the main study population.

Cancer type	Plasma B12 level groups (pmol/L)			
	150-600	601-800	801-1000	>1000
<b>Gastric/oesophageal, n</b>	1,764	53	11	23
Overall	Ref.	1.58 (1.16-2.15)	1.17 (0.55-2.45)	3.15 (1.92-5.17)
<1 year	Ref.	2.32 (1.54-3.50)	2.67 (1.19-5.97)	5.14 (2.75-9.62)
<b>Colorectal, n</b>	4,342	89	33	25
Overall	Ref.	0.91 (0.71-1.18)	1.68 (1.13-2.49)	1.31 (0.80-2.14)
<1 year	Ref.	1.18 (0.84-1.65)	2.44 (1.49-3.99)	1.65 (0.85-3.17)
<b>Liver, n</b>	337	30	16	17
Overall	Ref.	4.07 (2.61-6.36)	11.37 (6.62-19.53)	12.64 (7.22-22.13)
<1 year	Ref.	6.77 (3.24-14.12)	29.55 (14.08-62.01)	34.66 (16.50-72.81)
<b>Pancreas, n</b>	767	40	10	27
Overall	Ref.	2.40 (1.64-3.51)	2.28 (1.02-5.11)	7.42 (4.51-12.21)
<1 year	Ref.	5.92 (3.75-9.34)	6.27 (2.57-15.30)	19.60 (11.11-34.57)
<b>Lung, n</b>	3,820	101	19	26
Overall	Ref.	1.35 (1.08-1.70)	1.12 (0.66-1.89)	2.01 (1.32-3.05)
<1 year	Ref.	1.60 (1.11-2.32)	1.07 (0.40-2.86)	3.54 (2.00-6.26)
<b>Kidney, n</b>	590	16	6	≤5
Overall	Ref.	0.97 (0.50-1.88)	2.36 (0.98-5.71)	. (-.)*
<1 year	Ref.	0.60 (0.15-2.41)	. (-.)*	. (-.)*
<b>Prostate, n</b>	3,900	68	15	19
Overall	Ref.	0.91 (0.70-1.19)	0.95 (0.55-1.63)	1.07 (0.61-1.89)
<1 year	Ref.	1.34 (0.92-1.97)	1.32 (0.59-2.95)	2.09 (1.04-4.19)
<b>Myeloid malignancies, n</b>	2,190	128	63	84
Overall	Ref.	3.11 (2.53-3.81)	6.94 (5.23-9.20)	8.50 (6.41-11.27)
<1 year	Ref.	4.26 (3.21-5.64)	10.33 (7.11-15.02)	17.37 (12.60-23.96)
<b>Lymphatic leukaemia, n</b>	442	13	≤5	≤5
Overall	Ref.	1.50 (0.80-2.81)	. (-.)*	. (-.)*
<1 year	Ref.	1.51 (0.56-4.08)	. (-.)*	. (-.)*
<b>Multiple myeloma, n</b>	695	6	7	8
Overall	Ref.	0.38 (0.14-1.01)	0.84 (0.21-3.37)	2.11 (0.79-5.66)
<1 year	Ref.	. (-.)*	. (-.)*	. (-.)*

**Table 3.** Incidence rate ratios were based on the 537,936 persons with complete data on all covariates. Estimates were computed using persons with plasma levels B12 of 150-600 pmol/L as reference and adjusted for sex, age, Townsend quintile, smoking, alcohol use, and BMI. The analyses were stratified according to plasma B12 levels and length of follow-up (overall and <1 year). Abbreviations: BMI: body mass index. \*Too few events to compute estimates.

**Table 4.** Cumulative incidence proportions, person-years, number of cancer events, incidence rates, and adjusted incidence rate ratios (all with corresponding 95% confidence intervals) for the risk of cancer in the subcohort of first-time statin users.


First-time statin users	Plasma B12 level groups (pmol/L)			
	150-600	601-800	801-1000	>1000
<b>CIP (95% CI)</b>				
End of follow-up	15.94 (13.78-18.25)	11.27 (5.89-18.60)	12.68 (3.68-27.48)	26.43 (12.42-42.79)
1 year of follow-up	2.06 (1.80-2.36)	2.14 (.81-4.65)	1.90 (.16-8.82)	12.06 (4.90-22.70)
2 years of follow-up	3.33 (2.98-3.71)	3.74 (1.75-6.94)	1.90 (.16-8.82)	16.54 (7.72-28.25)
5 years of follow-up	7.07 (6.49-7.68)	6.33 (3.40-10.51)	8.35 (1.94-20.94)	16.54 (7.72-28.25)
<b>Person-years</b>				
Overall	44,965	860	222	184
<1 year	9,679	213	49	41
≥1-≤2 years	8,066	171	40	35
>2-≤4 years	16,083	303	73	66
≥5 years	11,138	174	59	42
<b>Cancer events</b>				
Overall	715	15	≤5	10
<1 year	207	≤5	≤5	6
≥1-≤2 years	109	≤5	≤5	≤5
>2-≤4 years	230	≤5	≤5	≤5
≥5 years	169	≤5	≤5	≤5
<b>IR/1,000 PYs (95% CI)</b>				
Overall	15.90 (14.78-17.11)	17.44 (10.51-28.92)	18.06 (6.78-48.11)	54.36 (29.25-101.04)
<1 year	21.39 (18.66-24.51)	23.51 (9.78-56.47)	20.30 (2.86-144.14)	146.17 (65.67-325.36)
≥1-≤2 years	13.51 (11.20-16.30)	17.59 (5.67-54.53)	. (-.)*	57.95 (14.49-231.71)
>2-≤4 years	14.30 (12.57-16.27)	13.18 (4.95-35.12)	27.48 (6.87-109.87)	. (-.)*
≥5 years	15.17 (13.05-17.64)	17.29 (5.58-53.60)	16.84 (2.37-119.58)	47.60 (11.90-190.32)
<b>Adj. IRR<sup>a</sup> (95% CI)</b>				
Overall	Ref.	1.24 (0.70-2.21)	1.56 (0.58-4.18)	4.71 (2.34-9.48)
<1 year	Ref.	1.10 (0.35-3.47)	1.23 (0.17-8.92)	8.92 (3.28-24.25)
≥1-≤2 years	Ref.	. (-.)*	. (-.)*	. (-.)*
>2-≤4 years	Ref.	. (-.)*	. (-.)*	. (-.)*
≥5 years	Ref.	. (-.)*	. (-.)*	. (-.)*

**Table 4.** <sup>a</sup>Incidence rate ratios were based on the 8,363 persons with complete data on all covariates. Estimates were computed using persons with a plasma B12 level of 150-600 pmol/L as reference and adjusted for sex, age, Townsend quintile, smoking, alcohol use, and BMI. The analyses were stratified according to plasma B12 levels and length of follow-up. \*Too few events to compute estimates. Abbreviations: BMI: body mass index; CI: confidence interval; CIP: cumulative incidence proportion; IR: incidence rate; IRR: incidence rate ratio; PYs: person-years.


## Figure 1.

**Figure 1.** Smoothed adjusted incidence rate ratio plot using a five-knot cubic spline transformation at 150, 400, 600, 800, and 1000 pmol/L. Plasma B12 levels of 400 pmol/L was used as reference. Models were adjusted for sex, age, Townsend quintile, smoking, alcohol use, and BMI. Dashed lines depict 95% confidence intervals. Panel 1A: overall incidence rate ratio. Panel 1B: incidence rate ratio after one year of follow-up. Abbreviations: BMI: body mass index.

1A



1B



# Cancer Epidemiology, Biomarkers & Prevention

**AACR** American Association  
for Cancer Research

## Elevated vitamin B12 levels and cancer risk in UK primary care: a THIN database cohort study

Johan F Arendt, Henrik Toft Sorensen, Laura J Horsfall, et al.

*Cancer Epidemiol Biomarkers Prev* Published OnlineFirst January 14, 2019.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/1055-9965.EPI-17-1136">10.1158/1055-9965.EPI-17-1136</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cebp.aacrjournals.org/content/suppl/2019/01/12/1055-9965.EPI-17-1136.DC1">http://cebp.aacrjournals.org/content/suppl/2019/01/12/1055-9965.EPI-17-1136.DC1</a>
<b>Author Manuscript</b>	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cebp.aacrjournals.org/content/early/2019/01/12/1055-9965.EPI-17-1136">http://cebp.aacrjournals.org/content/early/2019/01/12/1055-9965.EPI-17-1136</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.